Immix Biopharma, Inc.IMMXNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +58.38% | +38.24% | +26.72% | +4.16% | +8.50% |
| Weighted Average Shares Diluted Growth | +58.38% | +38.24% | +26.72% | +4.16% | +8.50% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +202.76% | +68.44% | -100.00% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +11.87% | +15.17% | -42.09% | -45.78% | -20.13% |
| Book Value per Share Growth | -43.96% | -41.57% | -72.88% | -81.30% | -56.60% |
| Debt Growth | +0.00% | +0.00% | -3.14% | -4.43% | +1.59% |
| R&D Expense Growth | +111.09% | -55.68% | -39.20% | +78.61% | +3.12% |
| SG&A Expenses Growth | +21.99% | +58.80% | +15.65% | +10.77% | +4.37% |